Skip to main content
. Author manuscript; available in PMC: 2013 Jun 18.
Published in final edited form as: Cancer Cell. 2012 Apr 17;21(4):547–562. doi: 10.1016/j.ccr.2012.02.028

Figure 6. Cells expressing low levels of BCL-xL were sensitive to triptolide in vivo.

Figure 6

A-D. H1437 (low BCL-xL expression; A, B) and HCC15 (high BCL-xL expression; C, D) NSCLC cell lines were grown as xenograft in NOD-SCID mice and the mice treated with triptolide or vehicle as indicated. A,C. Tumor volume. B,D. Survival curves. Error bars indicate standard deviation of tumor volume of 8–9 mice.

E. Triptolide treatment in vivo reduced MCL1 expression and induced PARP cleavage, a marker of apoptosis in tumors. Mice were treated either with vehicle alone or triptolide for 7 weeks (lanes marked Vehicle and triptolide 7 weeks, respectively), or with vehicle for 7 weeks followed by 1–3 days of triptolide (middle lanes).

F. Correlation between BCL-xL expression levels and resistance to epirubicin in ER-negative breast cancer patients (GEO accession number GSE16446). The distribution of BCL-xL expression levels, averaged over all BCL-xL probesets on the Affymetrix U133 Plus 2 array is displayed as a box plot for patients who obtained (N=16, blue dots, right column) or did not obtain (N=98, red dots, left column) pathological complete response to single agent epirubicin treatment. Whiskers of box-plots represent 5%–95% data span. Box-plots present median, 25th, and 75th percentiles of data.

See also Figure S5.